Health Technology
Nichi-Iko Pharmaceutical Co., Ltd.
In the news
- Japan's generic drugmakers have a China dependency problem Nov 5, 2019
- China extends drug patents to 25 years May 16, 2018
- Takeda-Shire deal shows it's US or bust for Japanese drugmakers May 10, 2018
- Nichi-Iko to sell generics in Philippines, Singapore Sep 2, 2017
- Teva Takeda Pharma shooting for $916m in sales in 2017 Apr 22, 2017 See more articles on Nichi-Iko Pharmaceutical Co., Ltd.
Business Summary
Nichi-Iko Pharmaceutical Co., Ltd. develops, manufactures, and markets generic pharmaceutical products. Its products are classified into Prescriptive and General Over-the-Counter (OTC) drugs. These products are used for the treatment of circulatory, digestive, respiratory, central and peripheral nervous systems problems. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 166,592M | 1,502.25M |
| Gross Profit | 33,158M | 299.00M |
| Operating income | 7,221M | 65.11M |
| Income before tax | 8,903M | 80.28M |
| Net income | 6,864M | 61.89M |
| EBITDA | 16,987M | 153.18M |
| Diluted EPS | 114.03 | 1.02 |
| Dividends Per Share | 30 | 0.27 |
| Total Assets | 306,838M | 2,772.17M |
| Total liabilities | 190,511M | 1,721.19M |
| Total equity | 116,323M | 1,050.93M |
| Operating cash flow | 23,811M | 214.71M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 127,021M | 143,513M | 149,263M | 164,717M | 166,592M |
| Gross Profit | 46,876M | 53,313M | 37,611M | 40,803M | 33,158M |
| Operating income | 9,619M | 12,910M | 10,026M | 13,200M | 7,221M |
| Income before tax | 9,488M | 15,359M | 5,963M | 9,067M | 8,903M |
| Net income | 6,592M | 11,031M | 4,796M | 8,069M | 6,864M |
| EBITDA | 20,265M | 24,200M | 17,091M | 22,179M | 16,987M |
| Diluted EPS | 110.13 | 184.01 | 84.08 | 142.92 | 114.03 |
| Dividends Per Share | 26.60 | 30 | 30 | 30 | 30 |
| Total Assets | 139,834M | 161,128M | 268,900M | 278,364M | 306,838M |
| Total liabilities | 65,347M | 78,531M | 185,725M | 190,819M | 190,511M |
| Total equity | 74,487M | 82,597M | 83,171M | 87,542M | 116,323M |
| Operating cash flow | 21,179M | 7,097M | -4,076M | 18,925M | 23,811M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 1,156.24M | 1,195.10M | 1,378.39M | 1,486.18M | 1,502.25M |
| Gross Profit | 426.70M | 443.96M | 347.32M | 368.15M | 299.00M |
| Operating income | 87.55M | 107.50M | 92.58M | 119.09M | 65.11M |
| Income before tax | 86.36M | 127.90M | 55.06M | 81.80M | 80.28M |
| Net income | 60.00M | 91.86M | 44.28M | 72.80M | 61.89M |
| EBITDA | 184.46M | 201.52M | 157.82M | 200.11M | 153.18M |
| Diluted EPS | 1.00 | 1.53 | 0.77 | 1.28 | 1.02 |
| Dividends Per Share | 0.24 | 0.24 | 0.27 | 0.27 | 0.27 |
| Total Assets | 1,166.01M | 1,433.58M | 2,413.17M | 2,617.43M | 2,772.17M |
| Total liabilities | 544.89M | 698.70M | 1,666.74M | 1,794.25M | 1,721.19M |
| Total equity | 621.11M | 734.88M | 746.39M | 823.14M | 1,050.93M |
| Operating cash flow | 192.78M | 59.10M | -37.64M | 170.75M | 214.71M |
Valuation Measures
| Mar 2019 | |
| PER | 12.71 |
| ROA | 2.34% |
| ROE | 6.73% |
| Operating margin | 4.33% |
| Profit margin | 4.12% |
Key executives
- President & Representative Director: Yuichi Tamura
- Director, Senior Head-Compliance & Internal Audit: Kenji Akane
- Director & General Manager-Administration: Noboru Inasaka
- Director & Managing Executive Officer: Takahiro Yoshikawa
- Auditor: Yoshihito Sugi
Shareholders
- TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (12.9%)
- Asset Management One Co., Ltd. (5.0%)
- Hokuhoku Financial Group, Inc. (4.3%)
- The Vanguard Group, Inc. (2.0%)
- Nipro Corp. (2.0%)
- Nomura Asset Management Co., Ltd. (1.8%)
- Sumitomo Mitsui DS Asset Management Co., Ltd. (1.8%)
- Nichi-Iko Pharmaceutical Co., Ltd. (1.4%)
- Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.3%)
- Goldman Sachs Asset Management LP (1.3%)
Contact Details
- Website:http://www.nichiiko.co.jp
- Phone: +81.76.432.2121
Related Companies
- Nichi-Iko Pharma Tech Co., Ltd.
- Elmed Co. Ltd.
- Nichi Iko Pharmaceutical Trust
- Nichi-Iko Pharmaceutical Employee Incentive Plan
- Nichiiko Pharma KK
- Nichiiko Osaka KK
- Yakuhan Pharmaceutical Co., Ltd.
- Sagent Pharmaceuticals, Inc.
- Kobayashi Pharmaceutical Industries Co. Ltd.
- Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
- Oriental Pharmaceutical Co., Ltd.
- Teikoku Medix Co., Ltd.
- Japan Galen, Inc.
- Maruko Pharmaceutical Co. Ltd.
- Nichiiko Pharmaceutical Employee Stock Pwnership Plan
Competitors
- Dr. Reddy's Laboratories Ltd.
- Hikma Pharmaceuticals Plc
- Amphastar Pharmaceuticals Inc
- Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Jan, 2020